Open-label
Open-label trial is a type of clinical trial in which both the researchers and participants are aware of the drug or treatment being given. This is in contrast to double-blind studies, where neither the researchers nor the participants know what treatment is being administered. Open-label trials can be used in various stages of drug development, including Phase I, Phase II, and Phase III.
Overview[edit | edit source]
In an open-label trial, all parties involved are aware of the treatment or intervention being given. This includes the researchers, the healthcare providers, and the participants. The term "open-label" comes from the fact that the label on the medication or treatment is "open" for everyone to see.
Open-label trials are often used when it would be unethical or impractical to conduct a double-blind study. For example, in a trial comparing the effectiveness of a new drug to a standard treatment, it may be considered unethical to withhold the standard treatment from participants in the control group. In such cases, an open-label trial may be used.
Advantages and Disadvantages[edit | edit source]
There are several advantages to open-label trials. They can be easier and less expensive to conduct than double-blind studies, as they do not require the creation of a placebo or the complex procedures needed to ensure blinding. They can also provide more realistic results, as they reflect the way the treatment would be used in the real world.
However, open-label trials also have several disadvantages. The main disadvantage is the potential for bias. Because everyone involved knows what treatment is being given, their expectations and perceptions can influence the results. This is known as observer-expectancy effect or confirmation bias. In addition, participants who know they are receiving a new or experimental treatment may experience a placebo effect, where their symptoms improve simply because they believe the treatment will work.
See also[edit | edit source]
References[edit | edit source]
| Open-label Resources | |
|---|---|
|
 |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
